Inhibrx Announces Preliminary Data From The Phase 1 Trial Of Inbrx-109 For The Treatment Of Ewing Sarcoma
Portfolio Pulse from Benzinga Newsdesk
Inhibrx, Inc. (NASDAQ:INBX) has announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with Irinotecan and Temozolomide for the treatment of advanced or metastatic, unresectable Ewing sarcoma. The disease control rate was 76.9% among the 13 patients evaluated. The treatment was well tolerated with the most common adverse events being diarrhea, nausea, and fatigue.
November 02, 2023 | 1:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inhibrx's announcement of positive preliminary data from the Phase 1 trial of INBRX-109 for Ewing sarcoma treatment could potentially boost investor confidence and positively impact the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence as they indicate progress in the company's pipeline and potential future revenue streams. Given that this is a Phase 1 trial, the results are preliminary but promising, which could lead to a positive short-term impact on Inhibrx's stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100